喹硫平治疗精神分裂症及相关疾病。

文章的细节

引用

复制到剪贴板

穆勒里德尔M, N, Strassnig M, Spellmann我,西弗勒斯E,穆勒HJ

喹硫平治疗精神分裂症及相关疾病。

Neuropsychiatr说请客。2007年4月;3 (2):219 - 35。doi: 10.2147 / nedt.2007.3.2.219。

PubMed ID

19300555 (在PubMed

]

文摘

喹硫平是由科学家们在1985年开发的阿斯利康(原捷利康)药品。收到官方的美国食品和药物管理局批准在1997年9月和2000年在德国批准。此后,喹硫平一直用于治疗严重精神疾病患者在大约70个国家包括加拿大,大多数西方欧洲国家和日本。喹硫平是一种dibenzothiazepine导数相对广泛的受体结合。它主要的亲和力脑羟色胺(5 ht)(2),内(H1)和多巴胺(1)和D(2)受体,温和的亲和力α(1)-和α(2)肾上腺素能受体,和次要muscarinergic M1受体亲和力;它演示了一个相当大的边缘系统选择性。这种受体入住率剖面相对更高的亲和力5 ht (2 a)受体与D(2)受体部分负责抗精神病和喹硫平的锥体外系副作用发生率低的特征。喹硫平的疗效降低精神分裂症的阳性和阴性症状已被证明在一些与安慰剂对照临床试验比较器。喹硫平也展示了强大的治疗功效的认知,anxious-depressive和积极的精神分裂症的症状。长期持续耐受性试验表明广泛的症状。 Quetiapine has also proven efficacy and tolerability in the treatment of moderate to severe manic episodes, and in the treatment of juveniles with oppositional-defiant or conduct disorders, and in the geriatric dementia population. Recent data indicate that quetiapine may also be effective in the treatment of bipolar depressive symptoms without increasing the risk of triggering manic episodes, and in borderline personality disorder. In comparison with other antipsychotics, quetiapine has a favorable side-effect profile. In clinical trials only small insignificant prolongations of the QT interval were observed. Weight-gain liabilities and new-onset metabolic side-effects occupy a middle-ground among newer antipsychotics. As a result of its good efficacy and tolerability profile quetiapine has become well established in the treatment of schizophrenia and manic episodes.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

喹硫平

药物靶点

药物	目标	类	生物	药理作用	行动
喹硫平	Alpha-2A肾上腺素能受体	蛋白质	人类	未知的	拮抗剂	细节